United Therapeutics Corp. (UTC) and Liquidia Technologies Inc. have been battling for close to a decade over their respective inhaled formulations ...

United Therapeutics navigates competition with solid Q1 results, revenue growth projections, and a solid balance sheet. Learn ...

Yutrepia's maker, Liquidia, has scheduled a first commercial shipment of the PH therapy to be available at specialty ...

This decision came after the full FDA approval of YUTREPIA inhalation powder for adults with pulmonary arterial hypertension ...

The FDA approved treprostinil (Yutrepia) inhalation powder for pulmonary arterial hypertension and pulmonary hypertension ...

Yutrepia is an inhaled dry powder formulation of treprostinil approved in the U.S. to improve exercise capacity in PAH and PH ...

Participants treated with atacicept for immunoglobulin A nephropathy (IgAN) achieved a 46% reduction from baseline in ...

Liquidia shares climbed 7.5% after disclosing that it is scheduled to make its first commercial shipment of Yutrepia inhalation powder, days after Food and Drug Administration approval. Shares were ...

Shares of Liquidia Technologies Inc (NASDAQ: LQDA) were up 9.6% following the announcement that the company is scheduled to make its first commercial shipment of YUTREPIA™ (treprostinil) inhalation ...

YUTREPIA now available to be prescribed to patients via specialty pharmaciesFDA approved YUTREPIA on May 23, 2025Court denies United Therapeutics’ request for preliminary injunction and a temporary ...

Liquidia Technologies Inc (NASDAQ:LQDA) saw its shares rise nearly 10% following news that it will begin its initial ...

In a report released today, Cory Jubinville, PhD from LifeSci Capital maintained a Buy rating on Liquidia Technologies (LQDA – Research Report), with a price target of $41.00. C ...